Inside the research
QuidelOrtho Corporation
QDEL Research profile · latest available data
Price overview
$10.94
▲ +0.25 (+2.3%)
| 52w hi | $35.38 |
|---|---|
| 52w lo | $9.96 |
| Vol | 1.38M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.43
| Short | -0.33 |
|---|---|
| Medium | -0.38 |
| Long | -0.71 |
computed 2026-09-27
Key fundamentals
QuidelOrtho Corporation
Healthcare · Medical Devices
| Market cap | $750.22M |
|---|---|
| Enterprise value | $3.70B |
| Forward P/E | 7.59x |
| EV / EBITDA | 7.64x |
| P / S (ttm) | 0.28x |
| Profit margin | -39.2% |
| Return on equity | -45.9% |
| Revenue growth | +2.8% |
| Debt / equity | 173.28 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | -0.10 | |
| Sector | +0.08 | |
| Technical | -0.29 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
Risk Metrics
| Beta vs SPX | 1.83 |
|---|---|
| Corr SPX | 0.37 |
| Annual vol | 79.0% |
| Annual ret | -40.3% |
| Sharpe | -0.51 |
| Max DD | -79.1% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-06 | Earnings Release, Exhibits | read |
| 2026-06-23 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-06-16 | Shareholder Vote | read |
| 2026-05-05 | Earnings Release, Exhibits | read |
| 2026-04-15 | Earnings Release, Exhibits | read |
| 2026-03-24 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-02-13 | Officer / Director Change | read |
| 2026-02-11 | Earnings Release, Exhibits | read |
| 2026-02-05 | Officer / Director Change | read |
| 2025-11-10 | Reg FD Disclosure, Exhibits | read |
| 2025-11-05 | Earnings Release, Exhibits | read |
| 2025-08-21 | Material Agreement, Material Obligation… | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-01 | Hanson Bryan Michael | EVP Global Port. Mgmt & M | Option exercise | 5.80K | — |
| 2026-07-01 | Hanson Bryan Michael | EVP Global Port. Mgmt & M | Withheld for tax | 2.10K | $38.11K |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 7 |
| Top-5 share | 99.3% |
| HHI | 4,055 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Fidelity / FMR LLC | $128.98M | 7.36M |
| State Street Corp | $52.17M | 2.98M |
| AQR Capital Management | $15.96M | 911.12K |
| Millennium Management | $12.65M | 722.48K |
| Capital Research / Capital World | $10.00M | 570.93K |
| Citadel Advisors | $1.60M | 91.20K |
| T. Rowe Price Group | $1.80K | 102.62K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2022–2025 · 4 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $3.00B | +21.7% | |
| Operating income | $139.10M | -63.8% | |
| Net income | -$10.10M | -17.7% | |
| Cash from ops | $105.20M | -49.3% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $10.69 | $10.95 | $10.42 | $10.94 | 1.38M |
| Sep 24 | $10.35 | $10.93 | $10.35 | $10.69 | 1.44M |
| Sep 23 | $10.92 | $11.10 | $10.32 | $10.34 | 1.11M |
| Sep 22 | $10.86 | $11.15 | $10.80 | $10.94 | 1.15M |
| Sep 21 | $10.78 | $10.97 | $10.40 | $10.86 | 1.07M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →